Partnerships & Alliances


Clinilabs and the Epilepsy Study Consortium has entered an collaborative agreement that allows them to provide integrated consultation and clinical drug development services to pharmaceutical and biotechnology companies conducting Phase I and II trials of antiepileptic drugs (AEDs).

The Epilepsy Study Consortium is a group of scientific investigators from academic medical research centers dedicated to accelerating the development of new therapies in epilepsy to improve patient care. The organization’s goals include building a partnership between academics, industry, and regulatory agencies, and optimizing clinical trial methodology in order to responsibly speed new treatments to patients.




Clinilabs is a Mortara Certified Partner capable of collecting, processing, and transmitting annotated ECG data compliant with ECG Warehouse requirements. The Clinilabs ECG Core Laboratory and integrated cardiac safety unit provide state-of-the-art facilities in support of ECG intensive and thorough QT (TQT) studies, operating to the standard required for upload of datasets into the FDA’s ECG Warehouse.

With Mortara Certified Partner status, Clinilabs has a competitive advantage in serving sponsors, and is now among the world’s leading vendors of ECG services. Sponsors that choose Clinilabs as their ECG Core Lab are assured of exceptional service and minimal risk of study failure.

Clinilabs and Cognitive Drug Research (CDR) formed a non-exclusive strategic alliance, bringing together two leaders in CNS clinical trials to provide an optimal environment for cognition assessment. CDR's gold standard cognition assessment equipment is permanently hosted at Clinilabs' premier clinical research unit in New York City. The creation of this 'super-site' offers clients a one-stop-shop for cognition assessment, bringing with it the advantages of ready trained site staff, expert consultation on cognition assessment and a full range of clinical trial site services.

H&J CRO International

Clinilabs has entered into a strategic alliance with H&J CRO International, a full-service CRO in China. This agreement allows Clinilabs and H&J to exchange knowledge and resources in order to provide clinical drug development services to pharmaceutical and biotechnology companies internationally.

H&J CRO International, Inc. is a global full-service CRO. The parent company, H&J (Beijing) Medinfor Consultants Ltd., was established in 2003. The company is headquartered in New Jersey U.S., with two branch offices located in Beijing and Shanghai, P.R. China. As of February 2009, H&J CRO had 95 full time employees, with 50% having received Ph.D. or Master’s Degrees in Medicine, Pharmacology, or Biostatistics. The company specializes in regulatory affairs, clinical trial research, clinical data management, SAS programming, biostatistics, and medical writing services. All members of the company’s senior management team have extensive R&D experience in various multinational pharmaceutical companies, with 8 – 24 years in industry. Their sophisticated practical experiences ensure that all projects are conducted efficiently and promptly. H&J’s high standards for quality and efficiency combined with intellectual ability from U.S. and China enable the company to provide cost-effective solutions in data management, SAS programming, biostatistics, and medical writing for phase I, II clinical trials in the U.S., and regulatory affairs services, clinical trial organization, study site monitoring and others CRO services for phase II, III, and IV clinical trials in China.